California-based Impax said that it plans to launch the product soon. US sales of the combined branded and generic 0.5mg, 1mg, 2mg and 3mg dosage forms were approximately $51 million in the 12 months ended March 2007, according to Wolters Kluwer Health.
“This is our third FDA approval this year and we are looking forward to adding our generic Xanax XR to the growing portfolio of our marketed products,” said Larry Hsu, Impax’s president and CEO.